Olympus Corporation, W. L. Gore & Associates, Inc. and ConMed Corporation jointly announced the upcoming transition of commercial support and distribution for the GORE VIABIL Biliary Endoprosthesis for endoscopic placement in the United States. This announcement follows the signed agreement between Gore and Olympus by which the exclusive global distribution rights for the VIABIL device are transferring to Olympus. Effective January 1, 2026, the distribution of the VIABIL device in the United States will transition to Olympus.
Olympus representatives will become the primary contact for VIABIL device orders as of that date. Until December 31, 2025, ConMed will continue to fully support the product, ensuring continuity of service and access for healthcare providers and patients. The VIABIL device is a fully covered self-expanding metal stent offering a differentiated alternative to achieve symptoms associated with biliary strictures.
